China
Microcyto微元合成, founded in 2021 and headquartered in China, is a biotech powerhouse focusing on synthetic biology for biomanufacturing. The company's niche lies in developing active pharmaceutical ingredients, high-value natural products, and bulk chemicals. It is effectively tapping into a range of sectors, including pharmaceuticals, cosmetics, agriculture, food, feed, and materials.
The company's core team comprises experts from top Chinese research institutions such as the Chinese Academy of Sciences, Tsinghua University, and Sichuan University. Microcyto's innovative approach has garnered substantial attention, evidenced by a significant Seed Round investment on 16 August 2023 from Matrix Partners China.
With collaborations spanning both domestic state-owned enterprises and international firms, Microcyto has established itself as a pivotal player in the biotechnological manufacturing sector. The company's growth trajectory and strategic industry partnerships present a compelling opportunity for further investment.
